3
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Teriparatida en el tratamiento sustitutivo del hipoparatiroidismo crónico. A propósito de un caso Translated title: Teriparatide in the substitutive treatment of chronic hypoparathyroidism. About a case

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Resumen Objetivo: Comunicar la experiencia del uso de teriparatida como tratamiento sustitutivo eficaz para el hipoparatiroidismo crónico. Material y métodos: Se plantea el caso clínico de un paciente con hipoparatiroidismo crónico postquirúrgico que presentaba previamente difícil control con el tratamiento convencional (sales de calcio y calcitriol) por lo que se inició teriparatida como tratamiento sustitutivo. Resultados: El paciente presentó valores analíticos del metabolismo fosfocálcico compatibles con la normalidad a partir de la 4º semana de tratamiento con teriparatida, permitiendo la suspensión de los tratamientos previos y manteniendo un buen control pasado un año del cambio de terapia. Conclusiones: Teriparatida es una opción eficaz para el tratamiento del hipoparatiroidismo crónico. Hemos observado una fase de latencia hasta iniciarse el efecto hormonal por lo que recomendamos monitorización analítica frecuente y desescalar gradualmente el tratamiento con calcitriol y sales de calcio para un adecuado control.

          Translated abstract

          Summary Objetive: To report experience in the use of teriparatide as an effective replacement therapy for chronic hypoparathy roidism. Material and methods: The clinical case of a patient with post-surgical chronic hypoparathyroidism who previously presented difficult control with conventional treatment (calcium salts and calcitriol) is presented, for which teriparatide was started as a substitute treatment. Results: The patient presented analytical values of phosphocalcic metabolism compatible with normality from the 4th week of treatment with teriparatide, allowing the suspension of previous treatments and maintaining good control one year after the change in therapy. Conclusions: Teriparatide is an effective option for treating chronic hypoparathyroidism. We have observed a latency phase until the hormonal effect begins, so we recommend frequent analytical monitoring and gradually reduce treatment with calcitriol and calcium salts for adequate control.

          Related collections

          Most cited references8

          • Record: found
          • Abstract: found
          • Article: not found

          European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults.

          Hypoparathyroidism (HypoPT) is a rare (orphan) endocrine disease with low calcium and inappropriately low (insufficient) circulating parathyroid hormone levels, most often in adults secondary to thyroid surgery. Standard treatment is activated vitamin D analogues and calcium supplementation and not replacement of the lacking hormone, as in other hormonal deficiency states. The purpose of this guideline is to provide clinicians with guidance on the treatment and monitoring of chronic HypoPT in adults who do not have end-stage renal disease. We intend to draft a practical guideline, focusing on operationalized recommendations deemed to be useful in the daily management of patients. This guideline was developed and solely sponsored by The European Society of Endocrinology, supported by CBO (Dutch Institute for Health Care Improvement) and based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) principles as a methodological base. The clinical question on which the systematic literature search was based and for which available evidence was synthesized was: what is the best treatment for adult patients with chronic HypoPT? This systematic search found 1100 articles, which was reduced to 312 based on title and abstract. The working group assessed these for eligibility in more detail, and 32 full-text articles were assessed. For the final recommendations, other literature was also taken into account. Little evidence is available on how best to treat HypoPT. Data on quality of life and the risk of complications have just started to emerge, and clinical trials on how to optimize therapy are essentially non-existent. Most studies are of limited sample size, hampering firm conclusions. No studies are available relating target calcium levels with clinically relevant endpoints. Hence it is not possible to formulate recommendations based on strict evidence. This guideline is therefore mainly based on how patients are managed in clinical practice, as reported in small case series and based on the experiences of the authors.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Management of Hypoparathyroidism: Summary Statement and Guidelines.

            Hypoparathyroidism is a rare disorder characterized by hypocalcemia and absent or deficient PTH. This report presents a summary of current information about epidemiology, presentation, diagnosis, clinical features, and management and proposes guidelines to help clinicians diagnose, evaluate, and manage this disorder.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.

              Hypoparathyroidism results in impaired mineral homoeostasis, including hypocalcaemia and hyperphosphataemia. Treatment with high-dose oral calcium and active vitamin D does not provide adequate or consistent control of biochemical indices and can lead to serious long-term complications. We aimed to test the efficacy, safety, and tolerability of once-daily recombinant human parathyroid hormone 1-84 (rhPTH[1-84]) in adults with hypoparathyroidism.
                Bookmark

                Author and article information

                Journal
                romm
                Revista de Osteoporosis y Metabolismo Mineral
                Rev Osteoporos Metab Miner
                Sociedad Española de Investigaciones Óseas y Metabolismo Mineral (Madrid, Madrid, Spain )
                1889-836X
                2173-2345
                December 2022
                : 14
                : 4
                : 104-106
                Affiliations
                [02] Plasencia Cáceres orgnameHospital Virgen del Puerto orgdiv1Servicio de Medicina Familiar y Comunitaria España
                [01] Plasencia Cáceres orgnameHospital Virgen del Puerto orgdiv1Servicio de Endocrinología, Diabetes y Nutrición España
                Article
                S1889-836X2022000400002 S1889-836X(22)01400400002
                10.4321/s1889-836x2022000400002
                7aab6c27-d9cb-4878-a090-4c1ddc0c07dc

                This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 International License.

                History
                : 10 January 2022
                : 06 July 2022
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 8, Pages: 3
                Product

                SciELO Spain

                Categories
                Caso Clínico

                teriparatida,hipoparatiroidismo,crónico,postquirúrgico,tratamiento,Teriparatide,hypoparathyroidism,chronic,post-surgical,treatment

                Comments

                Comment on this article